(Total Views: 220)
Posted On: 03/22/2021 6:13:00 PM
Post# of 182
NetworkNewsBreaks – Grapefruit USA Inc. (GPFT) Announces Increased Bioavailabilty for Flagship THC/CBD-Infused Cream
Grapefruit USA (OTCQB: GPFT), a premiere, fully licensed California-based cannabis company, has reached another technological milestone in the proprietary manufacturing process for its patented, disruptive Hourglass(TM) time-release THC+ cannabinoid delivery cream. In the announcement, the company noted that continued research and analysis of the manufacturing process have led to a substantial reduction in the size of the cream’s THC/CBD-infused particles. The mean particle size now measures 8.2 microns compared to previous samples, which averaged 33.1 and 29.9 microns. The company consistently analyzes the process with the intent of reducing the size of the infused particles, which leads to an increased bioavailability of Hourglass’ active ingredients. “We constantly strive to improve the quality of our Hourglass time-release THC+ cannabinoid delivery cream so our clientele is always the beneficiary of the best possible full-spectrum entourage experience we can deliver,” said Grapefruit CEO Bradley Yourist in the press release. “We performed several particle size analyses on the structure of the Hourglass cream as part of our manufacturing protocols in an effort to fine tune the process and produce a cream capable of delivering the best possible experience to Hourglass users. Our efforts have paid dividends. We are currently in the process of adapting our proprietary manufacturing protocols to our new hemp-derived CBD cream. No CBD competitor’s topical products will be able match the consistency and technology of our hemp-derived CBD creams to deliver Hourglass’ stellar results.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Grapefruit USA (OTCQB: GPFT), a premiere, fully licensed California-based cannabis company, has reached another technological milestone in the proprietary manufacturing process for its patented, disruptive Hourglass(TM) time-release THC+ cannabinoid delivery cream. In the announcement, the company noted that continued research and analysis of the manufacturing process have led to a substantial reduction in the size of the cream’s THC/CBD-infused particles. The mean particle size now measures 8.2 microns compared to previous samples, which averaged 33.1 and 29.9 microns. The company consistently analyzes the process with the intent of reducing the size of the infused particles, which leads to an increased bioavailability of Hourglass’ active ingredients. “We constantly strive to improve the quality of our Hourglass time-release THC+ cannabinoid delivery cream so our clientele is always the beneficiary of the best possible full-spectrum entourage experience we can deliver,” said Grapefruit CEO Bradley Yourist in the press release. “We performed several particle size analyses on the structure of the Hourglass cream as part of our manufacturing protocols in an effort to fine tune the process and produce a cream capable of delivering the best possible experience to Hourglass users. Our efforts have paid dividends. We are currently in the process of adapting our proprietary manufacturing protocols to our new hemp-derived CBD cream. No CBD competitor’s topical products will be able match the consistency and technology of our hemp-derived CBD creams to deliver Hourglass’ stellar results.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
